Sino-German Round Table Symposium on Cancer Precision Medicine in the Era of Big Data: Tianjin 2019
The “Sino-German Round Table Symposium on Cancer Precision Medicine in the Era of Big Data”, was successfully held by Tianjin Medical University Cancer Institute & Hospital (TMUCIH) and German Cancer Research Center (DKFZ) on June 19-20, 2019 in Tianjin.
Prof. Bo Xu, Vice President of TMUCIH, introduces invited guests, and Tianjin Medical University Cancer Institute & Hospital
Prof. Ping Wang, President of Tianjin Medical University Cancer Institute & Hospital, delivers a welcome speech
Prof. Michael Baumann, Chairman of German Cancer Research Center (DKFZ) , introduces DKFZ, delivers a welcome speech
Prof. Zhi Yao, Party Secretary of Tianjin Medical University, delivers a speech
Prof. Baiyu Zhang, Executive Deputy Director of the Sino-German Center for Research Promotion (SGC), introduces SGC and makes a speech
This symposium created a collaborative forum for interactive discussions and thought-provoking exchanges on cancer precision medicine, and brought together leading scientists and scholars from both institutions to give highlighted presentations, with the aim of promoting sustainable scientific research collaborations between China and Germany.
The symposium‘s academic exchange was rich and fruitful involving both basic and clinical research on neuro-oncology, pancreatic cancer, immunology, data integration, artificial intelligence, genomics, pediatric cancer, radiation oncology, lung cancer, gastrointestinal oncologyand immuno-oncology. It demonstrated outstanding achievements in the merging of different fields and the novel methods of diagnosis and treatment.
This symposium also provided an unique oppotunity for learning, sharing and exchanging the latest achievement and working experiences among clinicians, researchers and students. All the participants have benifited significantly from the in-depth discussion on cancer precision medicine.
TMUCIH and DKFZ are among the largest comprehensive cancer centers in China and Germany. The two institutions signed a MOU in November, 2018, aming to establish solid scientific research collaboration and to strive for breakthrough research results in cancer precision medicine by combining the strengths and resources from both sides. We are pleased to see that our exchange and cooperation is developing further through our collaborative efforts. We are looking forward to working together with DKFZ to pave the way for generating fruitful collaborations in the future. We anticipate reaching many milestones together.